Developmental toxicity of remdesivir, an anti‐COVID‐19 drug, is implicated by in vitro assays using morphogenetic embryoid bodies of mouse and human pluripotent stem cells
Birth Defects Research2022Vol. 115(2), pp. 224–239
Citations Over TimeTop 18% of 2022 papers
Abstract
Remdesivir impaired mouse and human MEBs at concentrations that are comparable to the therapeutic plasma levels in humans, urging further investigation into the potential impact of remdesivir on developing embryos.
Related Papers
- → The Culture of Mouse Embryonic Stem Cells and Formation of Embryoid Bodies(2010)35 cited
- → Induction of Human Induced Pluripotent Stem Cells to Cardiomyocytes Using Embryoid Bodies(2018)20 cited
- → Severe Inhibition ofin VitroCardiomyogenesis in Mouse Embryonic Stem Cells Ectopically Expressing EGAM1C Homeoprotein(2012)4 cited
- → [Differentiation of pluripotent embryonic stem cells in peritoneal cavity of irradiated mice].(2003)2 cited
- Differentiation of mouse embryonic stem cells into cardiomyogenic cells in cardiomyocytes(2012)